| Novartis–Astellas: micafungin, 202110– acquisition of ww product rights to Mycamine/Funguard by Sandoz from Astellas SIGNED |
2023-01-24 |
| DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-19 |
| DeuterOncology–Investsud: investment, 202301 financing round Series A toatlling €5.65m incl new investor Investsud Tech |
2023-01-19 |
| DeuterOncology–Newton Biocapital: investment, 202301 financing round Series A toatlling €5.65m incl existing investor Newton Biocapital |
2023-01-19 |
| DeuterOncology–Noshaq: investment, 202301 financing round Series A toatlling €5.65m incl new investor Noshaq |
2023-01-19 |
| DeuterOncology–SEVERAL: investment, 202301 financing round Series A €5.65m with Newton Biocapital + Noshaq + Investsud Tech |
2023-01-19 |
| Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems |
2023-01-18 |
| Blackford Analysis–Bayer: investment, 202301– acquisition by Bayer ANNOUNCED |
2023-01-18 |
| Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems |
2023-01-18 |
| InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital |
2023-01-17 |
| InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership |
2023-01-17 |
| InDevR–SEVERAL: investment, 202301 financing round Series B $9m from bioMérieux + Adjuvant Capital |
2023-01-17 |
| Mérieux–InDevR: VaxArray platform, 202301– excl distribution of VaxArray portfolio by bioMérieux in Europe |
2023-01-17 |
| Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery |
2023-01-11 |
| Boehringer–Minapharm: rec protein production technology, 202301– collab non-excl €na of ProBioGen + Boehringer on DirectedLuck transposase technology |
2023-01-10 |
| NextPoint Therapeutics–Bayer: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Leaps by Bayer |
2023-01-10 |
| NextPoint Therapeutics–Catalio Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Catalio Capital Management |
2023-01-10 |
| NextPoint Therapeutics–Harvard Univ: investment, 202301 financing round Series B totalling $80m incl existing + co-investor Binney Street Capital |
2023-01-10 |
| NextPoint Therapeutics–Invus Group: investment, 202301 financing round Series B totalling $80m incl new + co-investor Invus |
2023-01-10 |
| NextPoint Therapeutics–MPM Capital: investment, 202301 financing round Series B totalling $80m incl existing + co-investor MPM Capital Management |
2023-01-10 |
| NextPoint Therapeutics–PagodaTree Partners: investment, 202301 financing round Series B totalling $80m incl new + co-investor PagodaTree Partners |
2023-01-10 |
| NextPoint Therapeutics–PERSON: investment, 202301 financing round Series B totalling $80m incl existing + co-investor + co-founder Gordon Freeman |
2023-01-10 |
| NextPoint Therapeutics–Sanofi: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Sanofi Ventures |
2023-01-10 |
| NextPoint Therapeutics–SEVERAL: investment, 202301 financing round Series B $80m co-led by Leaps by Bayer + Sanofi Ventures |
2023-01-10 |
| NextPoint Therapeutics–Sixty Degree Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Sixty Degree Capital |
2023-01-10 |
| Albireo–Ipsen: investment, 202301– cash tender offer $952m at $42/share plus 1 CVR/share entitling to $10/CVR |
2023-01-09 |
| Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform |
2023-01-09 |
| Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea |
2023-01-09 |
| Evosep–Novo Group: investment, 202301 minority investment of $40m by Novo Holdings A/S |
2023-01-09 |
| Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO |
2023-01-09 |
| Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash |
2023-01-09 |
| Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED |
2023-01-08 |
| Acquifer Imaging–Bruker: investment, 202201 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners |
2023-01-05 |
| Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute |
2023-01-05 |
| Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners |
2023-01-05 |
| Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP |
2023-01-05 |
| BioVersys–AMR Action Fund: investment, 202301 financing round Series C extension with CHF8.2m? from AMR AF bringing total Series C to CHF32.6m |
2023-01-05 |
| ErVaccine–BPCE: investment, 202301 seed financing round totalling €4.5m (incl non-dilutive funds) incl investor Seventure |
2023-01-05 |
| ErVaccine–France (govt): investment, 202301 seed financing round totalling €4.5m (incl non-dilutive funds) incl investor Bpifrance |
2023-01-05 |
| ErVaccine–SEVERAL: investment, 202301 seed financing round €4.5m (incl non-dilutive funds) with Seventure + Bpifrance |
2023-01-05 |
| Volta Medical–Gilde Investment: investment, 202301 fianncing round Series B totalling €36m incl existing + co-investor Gilde Healthcare |
2023-01-05 |
| Volta Medical–Lightstone Ventures: investment, 202301 fianncing round Series B totalling €36m incl new + co-investor Lightstone Ventures |
2023-01-05 |
| Volta Medical–SEVERAL: investment, 202301 fianncing round Series B €36m led by Vensana Capital |
2023-01-05 |
| Volta Medical–Vensana Capital: investment, 202301 fianncing round Series B totalling €36m incl new + lead investor Vensana Capital |
2023-01-05 |
| Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker |
2023-01-04 |
| Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties |
2023-01-04 |
| Cellectis–EU (govt): credit, 202212– credit facility up to €40m in 3 tranches from EIB to develop allogeneic CAR T-cell products |
2022-12-28 |
| Affibody–EU (govt): credit, 202212– venture debt loan facility €20m from EIB supported by InvestEU programme |
2022-12-22 |
| Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED |
2022-12-22 |
| Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB |
2022-12-20 |
| Numares–SEVERAL: investment, 202212 financing round €20m from existing investors |
2022-12-20 |
| Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties |
2022-12-19 |
| S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG |
2022-12-16 |
| Minervax–Adjuvant Capital: investment, 202212 financing round totalling €22m incl exisiting + co-investor Adjuvant Capital |
2022-12-15 |
| Minervax–Bellevue: investment, 202212 financing round totalling €22m incl new + co-lead investor Pureos Bioventures |
2022-12-15 |
| Minervax–EU (govt): credit, 202212 loan facility €50m from EIB |
2022-12-15 |
| Minervax–LF Investment: investment, 202212 financing round totalling €22m incl exisiting + co-investor LF Investment |
2022-12-15 |
| Minervax–Novo Group: investment, 202212 financing round totalling €22m incl exisiting + co-investor Novo REPAIR Impact Fund |
2022-12-15 |
| Minervax–Sanofi: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sanofi Ventures |
2022-12-15 |
| Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures |
2022-12-15 |
| Minervax–Sunstone Life Science: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sunstone Life Science Ventures |
2022-12-15 |
| Minervax–Sweden (govt): investment, 202212 financing round totalling €22m incl exisiting + co-investor Industrifonden |
2022-12-15 |
| Minervax–Trill Impact: investment, 202212 financing round totalling €22m incl new + co-lead investor Trill Impact Ventures |
2022-12-15 |
| Minervax–Wellington Partners: investment, 202212 financing round totalling €22m incl exisiting + co-investor Wellington Partners |
2022-12-15 |
| ExeVir Bio–EU (govt): credit, 202212– venture debt financing €25m from EIB for develoment of nanobody Covid-19 therapy |
2022-12-14 |
| Ono Pharmaceutical–PrecisionLife: drug target discovery, 202212– collab r+d drug targets + biomarker discovery for CNS drugs |
2022-12-14 |
| Storm Therapeutics–Cambridge Innovation Capital: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor CIC |
2022-12-14 |
| Storm Therapeutics–Fast Track Initiative: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor FTI |
2022-12-14 |
| Storm Therapeutics–IP Group: investment, 202212 financing round Series B totalling $30m incl existing + co-investor IP Group plc |
2022-12-14 |
| Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures |
2022-12-14 |
| Storm Therapeutics–Otsuka: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Taiho Ventures LLC |
2022-12-14 |
| Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures |
2022-12-14 |
| Storm Therapeutics–Seroba: investment, 202212 financing round Series B totalling $30m incl existing + co-investor Seroba Life Sciences |
2022-12-14 |
| Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC |
2022-12-14 |
| Storm Therapeutics–Univ Tokyo: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor UTokyo IPC |
2022-12-14 |
| BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures |
2022-12-13 |
| BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures |
2022-12-13 |
| BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health |
2022-12-13 |
| BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises |
2022-12-13 |
| BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises |
2022-12-13 |
| BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital |
2022-12-13 |
| BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures |
2022-12-13 |
| Green Bioactives–Javelin Ventures: investment, 202212 seed financing round totalling £2.6m incl lead investor Eos Advisory LLP |
2022-12-13 |
| Green Bioactives–Milltrust International: investment, 202212 seed financing round totalling £2.6m incl co-investor Green Earth Ventures Fund |
2022-12-13 |
| Green Bioactives–Regenerate Ventures: investment, 202212 seed financing round totalling £2.6m incl co-investor RV Agtech Fund |
2022-12-13 |
| Green Bioactives–Scotland (govt): investment, 202212 seed financing round totalling £2.6m incl co-investor Scottish Enterprise |
2022-12-13 |
| Green Bioactives–SEVERAL: investment, 202212 seed financing round £2.6m led by Eos Advisory LLP |
2022-12-13 |
| Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand |
2022-12-13 |
| Chr. Hansen–Novozymes: investment, 202212– merger acquisition valuing Chr Hansen at DKK660.55/share ANNOUNCED |
2022-12-12 |
| Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share |
2022-12-12 |
| Bico–Sartorius: investment, 202212– directed share issue SEK487m (€45m) to existing investor Sartorius resulting 10.1% share + 8.5% of voting rights |
2022-12-08 |
| MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM |
2022-12-08 |
| Sartorius–Bico: laboratory equipment, 202212– collab RnD 3D cell printing technologies + digital soluitons for cell line development workflows |
2022-12-08 |
| Sartorius–Bico: laboratory equipment, 202212– distribution of Bico products in APAC region by Sartorius |
2022-12-08 |
| Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices |
2022-12-06 |
| Entact Bio–SEVERAL: investment, 202212 financing round Series A $81m co-led by Qiming Venture Partners USA + venBio Partners |
2022-12-06 |
| Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck |
2022-12-01 |
| BioNTech–Ryvu Therapeutics: small molecule immuno modulators, 202211– collab + license €20m upfront + research funding + milestones + royalties |
2022-11-30 |
| Ryvu Therapeutics–BioNTech: investment, 202211 equity investment €20m in connection with collab + license agreement by BioNTech |
2022-11-30 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg){kind=tracking}
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
